The newly funded research project will focus on the impact of Davunetide on a key pathology in PD, namely alpha-synuclein.
Allon said that a previous preclinical project, also sponsored by MJFF, showed that Davunetide had a positive effect in both in-vitro and in-vivo models of PD.
The company has already completed Phase 2 clinical trials in which the efficacy of Davunetide has been demonstrated in patients with amnestic mild cognitive impairment, a precursor to alzheimer’s disease, and cognitive impairment associated with schizophrenia.
MJFF chief program officer Todd Sherer said that because Davunetide is already in clinical trials for progressive supranuclear palsy, a rare progressive movement disorder, the potential exists to rapidly bridge to a clinical trial in PD.